Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $2.8 million.

  • BioLineRx's Other Accumulated Expenses rose 9.37% to $2.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.8 million, marking a year-over-year increase of 9.37%. This contributed to the annual value of $3.1 million for FY2024, which is 6.62% down from last year.
  • Latest data reveals that BioLineRx reported Other Accumulated Expenses of $2.8 million as of Q2 2025, which was up 58.02% from $1.8 million recorded in Q1 2025.
  • BioLineRx's 5-year Other Accumulated Expenses high stood at $3.4 million for Q3 2024, and its period low was $1.8 million during Q1 2025.
  • Its 3-year average for Other Accumulated Expenses is $2.6 million, with a median of $2.6 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first grew by 25.61% in 2024, then declined by 28.68% in 2025.
  • BioLineRx's Other Accumulated Expenses (Quarterly) stood at $3.4 million in 2023, then decreased by 6.62% to $3.1 million in 2024, then rose by 9.37% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q2 2025, $1.8 million for Q1 2025, and $3.1 million during Q4 2024.